PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Metrics to compare | PPGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPPGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −35.3x | −1.5x | −0.6x | |
PEG Ratio | −1.62 | −0.04 | 0.00 | |
Price/Book | 2.8x | 1.8x | 2.6x | |
Price / LTM Sales | 3.1x | 3.9x | 3.2x | |
Upside (Analyst Target) | 16.7% | 20.4% | 46.2% | |
Fair Value Upside | Unlock | 4.8% | 7.0% | Unlock |